Verrugas comuns que não responderam ao tratamento inicial, ou que recorreram após um curso anterior de tratamento, representam um desafio clínico específico. Esses casos refratários e recorrentes exigem uma abordagem escalonada além dos cuidados padrão de primeira linha.
O protocolo para este cenário centra-se na terapia de injeção intralesional local — agentes administrados diretamente no tecido da verruga em intervalos estruturados. Múltiplos agentes injetáveis têm evidências que apoiam seu uso neste contexto refratário e recorrente.
Os agentes específicos, seus critérios de seleção e o cronograma de tratamento são detalhados no protocolo estruturado completo.Resolução completa das verrugas em 4 semanas.
Resolução completa em 4 semanasLocal injections with bleomycin, 5-Fluorouracil (5-FU), and cidofovir are suggested for refractory and recurrent common warts.
A case-series study showed that after an average of 2.61 treatment cycles with intralesional injection of bleomycin (therapeutic dose at 3 U/ml and treatment interval at 3–4 weeks), all of the 250 periungual and subungual warts in 80 patients of whom 26 (32.50%) patients were either with no response to or recurrence after previous treatments were cleared and 65 (81.25%) patients experienced moderate pain during the treatment sessions, 155 (62.00%) treatment sites had transit dyspigmentation, and 3 (1.20%) treatment sites experienced reversible necrosis.
A prospective study reported that the cure rate of common warts with the injection of 5-FU, lidocaine, and epinephrine mixture (50 mg/ml 5-FU plus with lidocaine and epinephrine mixture at a ratio of 4:1) was higher than that of saline control (64.70% vs. 35.30%, p<0.05).
The result showed that lesional injection with 15 mg/ml cidofovir once a month, on average of 3.2 sessions, cleared relapsed and refractory warts in 276 of 280 patients.
The clinical criteria for cure of warts are complete clearance of lesions at 4 weeks and no recurrence for at least 6 months.
View source ↗